| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.10▼ | 1.10▼ | 1.10▼ | 1.12▼ | 1.14▼ |
| MA10 | 1.11▼ | 1.11▼ | 1.12▼ | 1.11▼ | 1.16▼ |
| MA20 | 1.13▼ | 1.12▼ | 1.11▼ | 1.13▼ | 1.34▼ |
| MA50 | 1.09▲ | 1.12▼ | 1.14▼ | 1.17▼ | 1.65▼ |
| MA100 | 1.13▼ | 1.19▼ | 1.23▼ | 1.35▼ | 1.30▼ |
| MA200 | 1.26▼ | 1.32▼ | 1.39▼ | 1.59▼ | 1.31▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.007▼ | -0.003▼ | -0.002▼ | 0.000▼ | -0.009▼ |
| RSI | 42.395▼ | 45.028▼ | 44.684▼ | 44.636▼ | 41.748▼ |
| STOCH | 4.444▼ | 4.375▼ | 6.042▼ | 57.449 | 37.004 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -63.934 | -70.774 |
| CCI | -83.854 | -79.587 | -82.014 | -51.802 | -60.237 |
|
Thursday, September 10, 2026 05:00 AM
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced ...
|
|
Wednesday, September 09, 2026 05:00 AM
Headshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development ...
|
|
Monday, August 10, 2026 01:10 PM
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE)-- IN8bio, Inc. (the "Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/09/26 | 1.12 | 1.1299 | 1.06 | 1.07 | 36,981 |
| 10/09/26 | 1.08 | 1.11 | 1.08 | 1.10 | 14,382 |
| 09/09/26 | 1.10 | 1.125 | 1.08 | 1.08 | 21,304 |
| 08/09/26 | 1.20 | 1.20 | 1.13 | 1.14 | 31,417 |
| 04/09/26 | 1.16 | 1.22 | 1.16 | 1.20 | 22,352 |
| 03/09/26 | 1.10 | 1.16 | 1.0962 | 1.16 | 41,536 |
| 02/09/26 | 1.09 | 1.11 | 1.085 | 1.10 | 6,725 |
| 01/09/26 | 1.10 | 1.13 | 1.08 | 1.09 | 19,948 |
| 31/08/26 | 1.01 | 1.13 | 1.01 | 1.10 | 36,919 |
| 28/08/26 | 1.04 | 1.05 | 1.03 | 1.035 | 23,999 |
|
|
||||
|
|
||||
|
|